Home > Rheumatology > Upadacitinib superior to abatacept for arthritis but sparks more side effects

Upadacitinib superior to abatacept for arthritis but sparks more side effects

Journal
New England Journal of Medicine
Reuters Health - 14/10/2020 - A 24-week phase 3 trial of AbbVie's upadacitinib shows that it produces more remissions and a better score on a rheumatoid arthritis (RA) scale than conventional treatment with abatacept. But the drug also appeared to be associated with concerning side effects, with one death, a stroke, two venous thromboembolic events and a greater tendency for elevated hepatic aminotransferase levels among the 303 volunteers getting that therapy. "Longer and larger trials are required in order to determine the effect and safety of upadacitinib in patients with rheumatoid arthritis," the research team led by Dr. Andrea Rubbert-Roth of the Cantonal Hospital in St. Gallen, Switzerland, wrote in the New England Journal of Medicine, where the study appears. AbbVie paid for the study, known as SELECT-CHOICE. It is "the first head-to-head trial in RA patients who failed previous biologic DMARD (disease-modifying antirheumatic drug) therapy," Dr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on